

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Jordan et al. Confirmation No.: 9124  
Serial No.: 10/561,153  
Filing Date: April 5, 2006  
For: COMPOUNDS, COMPOSITIONS, AND METHODS FOR  
TREATMENT AND PREVENTION OF ORTHOPOXVIRUS  
INFECTIONS AND ASSOCIATED DISEASES  
Examiner: Bianchi, K.  
Group Art Unit: 1626



Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450



**INFORMATION DISCLOSURE STATEMENT**



Sir:



Applicants respectfully submit this Information Disclosure Statement pursuant to 37 C.F.R. §§ 1.97 and 1.98 in order to comply with the duty of disclosure under 37 C.F.R. § 1.56.



Applicants respectfully submit that the following compounds listed in Tables 1 and 2 within the specification were commercially purchased prior to the priority date of the above-mentioned application:



Example Number	R <sub>6</sub>	*NMR	**Mass Spec	Name
2		<sup>1</sup> H NMR in DMSO-d <sub>6</sub> : δ 11.41(brs); 11.15(brs); 8.77(d of d, 2H); 7.75(d, 2H); 5.77(brs, 2H); 3.27 (brs, 4H), 1.15(brs, 2H); 0.25(m, 1H); 0.03(brs, 1H)	308 (M-H)-	N-(3,3a,4,4a,5,5a,6,6a,-octahydro-1,3-dioxo-4,6-ethenocycloprop[ <i>f</i> ]isoidol-2(1H)-yl)-4-pyridinecarboxamide
3		***	385 (M-H)-	4-Bromo-N-(3,3a,4,4a,5,5a,6,6a,-octahydro-1,3-dioxo-4,6-ethenocycloprop[ <i>f</i> ]isoidol-2(1H)-yl)-benzamide


Example Number	R <sub>6</sub>	*NMR	**Mass Spec	Name
4		<sup>1</sup> H NMR in DMSO-d <sub>6</sub> : δ 11.13(brd, 1H); 10.89(brd, 1H); 7.99(s, 1H); 7.82 – 7.76(m, 2H); 7.43(t, 1H); 5.72(s, 2H); 3.22-3.08(m, 4H); 1.19(brs, 2H); 0.21(m, 1H); 0.17(brs, 1H)	385 (M-H)-	3-Bromo-N-(3,3a,4,4a,5,5a,6,6a,8-octahydro-1,3-dioxo-4,6-ethenocycloprop[7]isondol-2(1H)-yl)-benzamide
5		<sup>1</sup> H NMR in DMSO-d <sub>6</sub> : δ 11.21(brd, 1H); 10.98(brd, 1H); 7.92(s, 1H); 7.85(d, 1H); 7.71(d, 1H); 7.58(t, 1H); 5.79(brs, 2H); 3.29-3.15(m, 4H); 1.19-1.15(m, 2H); 0.26(m, 1H); 0.10(brs, 1H)	341 (M-H)-	3-Chloro-N-(3,3a,4,4a,5,5a,6,6a,8-octahydro-1,3-dioxo-4,6-ethenocycloprop[7]isondol-2(1H)-yl)-benzamide

Example Number	R <sub>6</sub>	*NMR	**Mass Spec	Name
8		<sup>1</sup> H NMR in DMSO-d <sub>6</sub> ; δ 11.16(brd, 1H); 10.91(brd, 1H); 7.90(d, 2H); 7.61(d, 2H); 5.79(s, 2H); 3.28(m, 4H), 1.17(s, 2H); 0.26(m, 1H); 0.07(s, 2H)	341 (M-) <sup>-</sup> H-	4-Chloro-N-(3,3a,4,4a,5,5a,6,6a,-octahydro-1,3-dioxo-4,6-ethenocycloprop[ <i>f</i> ]isoidol-2(1H)-yl)-benzamide
11		<sup>1</sup> H NMR in DMSO-d <sub>6</sub> ; δ 10.87(brd, 1H); 7.87(d, 2H); 7.05(d, 2H); 5.78(br, 2H); 3.84(s, 3H); 3.30(s, 4H), 1.16(m, 2H); 0.25(m, 1H); 0.07(brs, 1H)	339 (M+H) <sup>+</sup>	4-Methoxy-N-(3,3a,4,4a,5,5a,6,6a,-octahydro-1,3-dioxo-4,6-ethenocycloprop[ <i>f</i> ]isoidol-2(1H)-yl)-benzamide

Example Number	R <sub>6</sub>	*NMR	**Mass Spec	Name
22		***	***	4-Methyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[fl]isoidol-2(1H)-yl)-benzamide
23		***	***	3-Bromo-N-(1',3',3'a,4',7,7'a-hexahydro-1',3'-dioxospiro[cyclopropane-1,8'-[4,7]methano[2H]isoidol]-2'-yl)-benzamide

Example Number	R <sub>6</sub>	*NMR	**Mass Spec	Name
24		***	***	N-(3,3a,4,4a,5,5a,6,6a,-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoidol-2(1H)-yl)-tricyclo[3.3.1.1.3,7]decane-1-carboxamide
25		***	***	N-(3,3a,4,4a,5,5a,6,6a,-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoidol-2(1H)-yl)-benzeneacetamide

Example Number	R <sub>6</sub>	*NMR	**Mass Spec	Name
26		***	***	4-Bromo-N-(1,3,3a,4,7,7a-hexahydro-1,3,-dioxo-4,7-methano-2H-isoindol-2-yl)-benzamide
27		***	***	2,4-Dichloro-N-(1,3,3a,4,7,7a-hexahydro-1,3,-dioxo-4,7-methano-2H-isoindol-2-yl)-benzamide

Example Number	R <sub>6</sub>	*NMR	**Mass Spec	Name
41				2,4-Dimethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[ <i>f</i> ]isoidol-2(1 <i>H</i> )-yl)-thiazole-5-carboxamide



This Information Disclosure Statement is being mailed before the mailing date of the first Office Action on the merits, and thus, pursuant to 37 C.F.R. § 1.97(b), Applicants respectfully request that the information be expressly considered during the prosecution of this application.

It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Director is authorized to charge Deposit Account No. 50-0540 for such fees. Early and favorable action is earnestly solicited.

Dated: June 25, 2009

Respectfully submitted,

/Charles Achkar/  
Charles Achkar, Reg. No. 43,311  
Attorneys for Applicant  
KRAMER LEVIN NAFTALIS & FRANKEL LLP  
1177 Avenue of the Americas  
New York, New York 10036  
(212) 715-9100 (phone)  
(212) 715-8000 (fax)